Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2017

View Archived Issues

Janssen describes anxiolytic candidate JNJ-54717793, a selective Ox1R antagonist

Genentech discovers new, potent and selective inhibitors of Nav1.7

Grid Therapeutics signs license agreement with Duke University for CFH antibodies for cancer

Inactivation of PERVs to eliminate cross-species viral transmission in xenotransplantation

Novel VLP zDIII-based subunit Zika vaccine demonstrates high immunogenicity in mice

Teikoku Pharma reports topline phase II results for TPU-006 patch in post-surgical pain

Apic Bio launches with focus on therapies for alpha-1 antitrypsin deficiency

GT Biopharma announces reverse stock split

Novel series of GyrB/ParE inhibitors discovered for bacterial infections including gonorrhea

Cure Pharmaceutical reports progress in development of ODS formulation of isoniazid

FDA grants orphan drug designation to EPX-300 for Dravet syndrome

Emcure Pharmaceuticals presents new IDO-1, TDO inhibitors

Intra-Cellular Therapies receives FDA opinion on lumateperone program in schizophrenia

Novel retinoic acid receptor ligands discovered at Galderma

ViiV Healthcare divulges new HIV maturation inhibitors

Bamichem, Samjin Pharmaceutical, Incheon National University patent VEGFR-2, B-Raf, C-Raf inhibitors

GlaxoSmithKline discovers new phosphatidylinositol 3-kinase inhibitors

Caprion collaborates with FNIH Biomarkers Consortium on Cerebrospinal Fluid Proteomics Project

Otsuka and Mylan sign delamanid license agreement for low- and middle-income countries

Symic Bio initiates phase II MODIFY2 study of SB-061 for osteoarthritis

E.U. approval for Kisqali with an aromatase inhibitor for first-line HR+/HER- breast cancer

ImmunoCellular refocuses resources on Stem-to-T-Cell research program

FDA grants priority review to emicizumab BLA for hemophilia A

Orchard's OTL-101 designated Promising Innovative Medicine in U.K. for ADA-SCID

First-in-human study evaluates fluorothyazinone in healthy volunteers

Daewoong studies DWP-14012 for erosive GERD in new phase II trial

Bonti initiates phase II LANTERN-1 study of EB-001 to reduce musculoskeletal pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...